Harrison K L, Wood M, Lees N P, Hall C N, Margison G P, Povey A C
School of Epidemiology and Health Sciences, Medical School, University of Manchester, Oxford Road, Manchester M13 9PT, United Kingdom.
Chem Res Toxicol. 2001 Mar;14(3):295-301. doi: 10.1021/tx000071b.
N7-Methyldeoxyguanosine (N7-MedG) in DNA is a biomarker of exposure to environmental and endogenous methylating agents and may be of use in epidemiological studies. To quantitate N7-MedG in human samples, a sensitive assay system that uses only small quantities of DNA (<10 microg) is required. To this end, polyclonal antibodies against the imidazole ring-opened form of N7-MedG have been used to develop a highly sensitive immunoslot blot (ISB) assay. The limit of detection of the assay is 0.10 micromol of N7-MedG/mol of deoxyguanosine (dG) using 1 microg of DNA per analysis. The method was optimized using in vitro-methylated calf thymus DNA and then applied to a study of DNA methylation in liver and brain tissues of mice following a single iv dose of the antitumor agent Temozolomide. The amount of N7-MedG in both tissues was strictly proportional to dose over a range of 10-200 mg of Temozolomide/kg of body weight. The ISB assay was then validated using pyloric DNA of rats treated with N-methyl-N'-nitro-N-nitrosoguanidine and DNA samples from human bladder tumors, for both of which N7-MedG levels had already been quantitated by an HPLC/(32)P-postlabeling method previously described. The results showed a high degree of correlation (r = 0.98) between the two assays. The ISB assay was then applied to a range of human samples. A series of peripheral blood mononuclear cell DNA samples from cancer patients following treatment with Temozolomide had levels of N7-MedG ranging from 0.22 to 320 micromol/mol of dG. DNA samples from colon carcinoma and normal colorectal mucosa from individuals not known to be exposed to methylating agents contained levels of 0.11-1.34 micromol of N7-MedG/mol of dG. The ISB assay offers the potential for the rapid and high-throughput analysis of DNA obtained from routine biopsies and blood samples, thus enabling the determination of the extent of human exposure to environmental and endogenous sources of methylating agents in large-scale biomonitoring studies.
DNA中的N7-甲基脱氧鸟苷(N7-MedG)是暴露于环境和内源性甲基化剂的生物标志物,可能在流行病学研究中有用。为了定量人类样本中的N7-MedG,需要一种仅使用少量DNA(<10微克)的灵敏检测系统。为此,已使用针对N7-MedG咪唑环开环形式的多克隆抗体开发了一种高度灵敏的免疫斑点印迹(ISB)检测方法。每次分析使用1微克DNA时,该检测方法的检测限为0.10微摩尔N7-MedG/摩尔脱氧鸟苷(dG)。该方法使用体外甲基化的小牛胸腺DNA进行了优化,然后应用于研究单次静脉注射抗肿瘤药物替莫唑胺后小鼠肝脏和脑组织中的DNA甲基化情况。在10-200毫克替莫唑胺/千克体重范围内,两种组织中N7-MedG的含量与剂量严格成正比。然后,使用用N-甲基-N'-硝基-N-亚硝基胍处理的大鼠幽门DNA和人类膀胱肿瘤的DNA样本对ISB检测方法进行了验证,此前已通过先前描述的HPLC/(32)P后标记方法对这两种样本的N7-MedG水平进行了定量。结果表明两种检测方法之间具有高度相关性(r = 0.98)。然后将ISB检测方法应用于一系列人类样本。替莫唑胺治疗后的癌症患者的一系列外周血单核细胞DNA样本中,N7-MedG的水平范围为0.22至320微摩尔/摩尔dG。来自未知暴露于甲基化剂的个体的结肠癌和正常结肠直肠黏膜的DNA样本中,N7-MedG的含量为0.11-1.34微摩尔/摩尔dG。ISB检测方法为从常规活检和血液样本中获得的DNA进行快速高通量分析提供了潜力,从而能够在大规模生物监测研究中确定人类暴露于环境和内源性甲基化剂的程度。